Compare · MDLN vs PYPD
MDLN vs PYPD
Side-by-side comparison of Medline Inc. (MDLN) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PYPD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $53.81B, about 419.8x PYPD ($128.2M).
- Over the past year, MDLN is up 3.4% and PYPD is up 74.6% - PYPD leads by 71.2 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 6 for PYPD).
- MDLN has more recent analyst coverage (25 ratings vs 7 for PYPD).
PerformanceMDLN+3.42%PYPD+66.20%
2025-12-17+0.00%2026-11-11
- Company
- Medline Inc.
- PolyPid Ltd.
- Price
- -
- -
- Market cap
- $53.81B
- $128.2M
- 1M return
- +18.10%
- +33.30%
- 1Y return
- +3.42%
- +74.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 7
PYPD
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest MDLN
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medline Reports Third Quarter and Nine Months 2026 Results
- Medline announces participation in the 2026 Jefferies Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 8-K filed by Medline Inc.
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- Large owner Gic Private Ltd sold $274,767,093 worth of shares (7,816,987 units at $35.15) (SEC Form 4)
Latest PYPD
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
- Oppenheimer initiated coverage on PolyPid Ltd. with a new price target
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
- SEC Form 6-K filed by PolyPid Ltd.